Manufacturer: LILLY manufactures Evista.
The uses of Evista include:
Product Origin: EU (Turkey)
This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.
Evista is used for: Treating and preventing osteoporosis (bone thinning) in women past menopause.
Raloxifene affects the cycle of bone formation and breakdown in the body, and reduces loss of bone tissue.
Raloxifene is used to treat or prevent osteoporosis in postmenopausal women. Raloxifene is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are otherwise at risk of invasive breast cancer.
Evista is prescribed to treat and prevent osteoporosis, the brittle-bone disease that strikes some women after menopause. A variety of factors promote osteoporosis. The more factors that apply to you, the greater your chances of developing the disease. These factors include:
Caucasian or Asian descent
A diet low in calcium
An inactive lifestyle
Osteoporosis in the family
Raloxifene (ral-OX-i-feen) is used to help prevent and treat thinning of the bones (osteoporosis) only in postmenopausal women.
It works like an estrogen to stop the bone loss that can develop in women after menopause, but it does not increase the bone density as much as daily 0.625 mg doses of conjugated estrogens. Raloxifene will not treat hot flashes of menopause and may cause hot flashes to occur. Also, raloxifene does not stimulate the breast or uterus as estrogen does.
Raloxifene lowers the blood concentrations of total and low-density lipoprotein (LDL) cholesterol, the bad cholesterols, but it does not increase concentrations of high-density lipoprotein (HDL) cholesterol, the good cholesterol, in your blood.